GET DAILY SIGNALSSensus Healthcare (SRTS) +10% Rebound Sets Up Earnings Watch
Key Takeaways
- SRTS shares rose roughly 10% over the trailing 30-day period, rebounding from levels near the 52-week low following a sharp single-session gain in early November.
- The stock remains below its late-August peak near $3.54 after a multi-week decline through September and October.
- Third-quarter 2026 results, scheduled for November 12, are the key near-term catalyst, with consensus near -$0.06 EPS on about $6.6 million in revenue.
- Eight SRT systems deferred from the second quarter because of financing-approval timing are expected to be recognized in the third quarter, supporting a sequential revenue rebound.
- Dedicated CPT reimbursement codes for superficial radiotherapy took effect January 1, 2026, and a proposed CMS increase in hospital-based delivery rates supports the reimbursement outlook.
- Analyst consensus is "Strong Buy" with an average price target near $5.38, though several firms trimmed targets after second-quarter results.
- For additional detail on valuation and expectations, review Sensus Healthcare's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see top-performing automated trading strategies across the market.
Company Background and Market Focus
Sensus Healthcare, Inc. is a medical device company based in Boca Raton, Florida, that develops and markets non-invasive treatments for non-melanoma skin cancer and keloids. Its core technology is superficial radiotherapy (SRT) and image-guided SRT (IG-SRT), delivered through the SRT-100, SRT-100+, and SRT-100 Vision platforms. The SRT-100 Vision integrates high-frequency ultrasound imaging, volumetric tumor analysis, and dosimetry planning to support clinicians. The company also markets Sensus Link, a cloud software platform aimed at building recurring revenue, and offers equipment under its Fair Deal Agreement program. Investors follow SRTS for its position in dermatology and radiation oncology, its expansion into international markets, and the reimbursement changes reshaping demand for its systems. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
SRTS Stock Performance Over 30 Days and the Quarter
Over the trailing 30 days, SRTS advanced approximately 10%, from a closing level near $2.98 in early October to about $3.28. The move was not linear: shares drifted through the low $2.70s into late October, approaching the lower end of the 52-week range, before staging a sharp rebound. On a quarterly basis, the stock is up roughly 12% from the $2.92 area in early August, but that headline gain understates the volatility. SRTS rallied to about $3.54 in late August, then gave back those gains through September and much of October before recovering. The result is a choppy, range-bound pattern in which the stock has yet to reclaim its late-summer high.
Drivers Behind the Recent 30-Day Advance
The most visible driver over the past month was positioning ahead of the third-quarter earnings report, scheduled for November 12. Management has said that eight units whose revenue was deferred out of the second quarter because of third-party financing delays were subsequently approved and are expected to be recognized in the third quarter, at an average selling price near $250,000 each. That timing shift pointed to a potential sequential revenue recovery, a theme analysts and investors began pricing in. The company's October 29 announcement confirming the earnings date and business update call refocused attention on the near-term catalyst. Broader reimbursement developments also remained supportive, including the dedicated SRT CPT codes that took effect January 1, 2026 and a proposed CMS increase of about 26% in the hospital-based delivery code. The sharp early-November rebound followed a period in which the stock traded near multi-year lows, suggesting bargain-hunting and earnings anticipation rather than a single company-specific announcement.
Influences on Performance Across the Quarter
The quarter's larger narrative centered on a difficult second-quarter report and the company's transition to a new reimbursement environment. On August 13, Sensus reported second-quarter revenue of $2.29 million, down about 69% year over year, and a net loss of $8.75 million, as financing delays pushed eight unit sales into the third quarter and sales to its historically largest customer were absent. Several analysts lowered price targets in response — Alliance Global Partners moved to $5.50 from $6.50, and Lake Street to $4.00 from $4.50 — while maintaining Buy ratings. The company also disclosed a lawsuit against SkinCure Oncology alleging breach of contract. Offsetting these pressures, management highlighted a strengthening pipeline, rising adoption of Sensus Link, growing Fair Deal Agreement utilization, and international interest across Asia-Pacific markets. The dedicated CPT codes and the proposed hospital-rate increase provided a structural tailwind that helped the stock recover from its October lows.
Key Items on the Horizon for SRTS
The clearest near-term catalyst is the third-quarter earnings report on November 12, including revenue recognition from the deferred units, gross-margin trends, and any updated commentary on the sales pipeline and profitability timeline. Investors are also likely to monitor the finalization of CMS reimbursement rates, the pace of Sensus Link activations, and international expansion, particularly in Australia and other Asia-Pacific markets. Key risks include continued customer concentration challenges, pressure on gross margin from product mix, and whether the company can convert a stronger pipeline into sustained, sequential revenue growth. As always, these factors are informational and should not be interpreted as investment recommendations.
Reviewing Automated Trading Approaches
From what I see, Tickeron’s Trending AI Robots page offers a useful way to compare systematic strategies that have performed well across thousands of tickers. I have used it occasionally to identify data-driven approaches that complement my own fundamental work on names like SRTS. The robots cover different timeframes and styles, providing a starting point rather than any assurance of results, yet the focused selection helps narrow options when building or refining a broader toolkit.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SRTS's RSI Oscillator recovers from oversold territory
The RSI Indicator for SRTS moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 29 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 226 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SRTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRTS as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for SRTS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 27 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.228) is normal, around the industry mean (4.204). P/E Ratio (-2.926) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. SRTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of skin cancer treatment products
Industry MedicalNursingServices
Advertisement